High Costs Associated With Physician Burnout, Attrition

Share this content:
High Costs Associated With Physician Burnout, Attrition
High Costs Associated With Physician Burnout, Attrition

TUESDAY, Nov. 21, 2017 (HealthDay News) -- Physicians who are experiencing burnout are more than twice as likely to leave their organization within two years, and this is associated with significant economic costs, according to a report from the American Medical Association.

Maryam Hamidi, Ph.D., and Mickey Trockel, M.D., Ph.D., from the Stanford Medicine WellMD Center, note that almost 60 physicians would leave Stanford Medicine within two years if nothing were done to address burnout. For the 58 physicians who would leave Stanford, the economic loss over two years would range from $15.5 million to $55.5 million.

The researchers surveyed a random sample of physicians in 2013 on burnout, work hours, surgical specialty, anxiety, depression, and sleep-related impairment. They reviewed data in 2015 to identify which physicians had left the organization. The group of physicians that had left had slightly higher anxiety, depression, and sleep-related impairment scores, but there was no significant between-group difference. Burnout was identified as the variable that explained the difference: compared with those not experiencing burnout, physicians with burnout in 2013 were more than twice as likely to leave the organization. Twenty-three percent of physicians who left Stanford had burnout, compared with 16 percent of those who did not leave the organization.

"Aside from the humanistic reasons, we're also trying to make a point that organizations should invest money into preventing burnout," Hamidi said in a statement.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »